{"log_id": 1264449023973480316, "direction": 0, "words_result_num": 28, "words_result": [{"probability": {"variance": 0.059537, "average": 0.774185, "min": 0.409216}, "location": {"width": 164, "top": 285, "height": 34, "left": 326}, "words": "何成分救者"}, {"probability": {"variance": 0.045945, "average": 0.860893, "min": 0.397285}, "location": {"width": 141, "top": 368, "height": 32, "left": 340}, "words": "【意事项】"}, {"probability": {"variance": 0.00192, "average": 0.9706, "min": 0.875985}, "location": {"width": 162, "top": 445, "height": 34, "left": 331}, "words": "一般注意事项"}, {"probability": {"variance": 0.041405, "average": 0.851354, "min": 0.371537}, "location": {"width": 1058, "top": 516, "height": 45, "left": 331}, "words": "尿胃的风险性日于有尿留的危险,本品用于临床上有明膀流出道视过"}, {"probability": {"variance": 0.032715, "average": 0.883813, "min": 0.443163}, "location": {"width": 1060, "top": 578, "height": 41, "left": 326}, "words": "的患者。出于有胃的的风险,本品应用了有胃肠道梗阻性疾病,如幽门狭窄的患者(参"}, {"probability": {"variance": 0.049844, "average": 0.859856, "min": 0.419841}, "location": {"width": 137, "top": 644, "height": 34, "left": 326}, "words": "见【忌】"}, {"probability": {"variance": 0.027962, "average": 0.880108, "min": 0.416205}, "location": {"width": 1058, "top": 706, "height": 43, "left": 329}, "words": "骨动减的者:与其它抗当类药物相似,本慎用于肠蟠动减弱的"}, {"probability": {"variance": 0, "average": 0.877001, "min": 0.877001}, "location": {"width": 32, "top": 756, "height": 29, "left": 326}, "words": "者"}, {"probability": {"variance": 0.032874, "average": 0.858461, "min": 0.380066}, "location": {"width": 818, "top": 813, "height": 48, "left": 338}, "words": "已控的窄角性光:本品慎月干正治疗的角性青光患考"}, {"probability": {"variance": 0.028666, "average": 0.876347, "min": 0.36008}, "location": {"width": 1058, "top": 893, "height": 48, "left": 329}, "words": "肝功能和肾功能减的:对干肝功能或肾功能明显减退者,建议本品的用药量为"}, {"probability": {"variance": 0.033648, "average": 0.86934, "min": 0.428219}, "location": {"width": 1056, "top": 955, "height": 43, "left": 326}, "words": "每日21mg参见夏药理毒理】的“临床药理学”【代动力学】的“特殊人群中的药代动力学\")"}, {"probability": {"variance": 0.032794, "average": 0.863292, "min": 0.447184}, "location": {"width": 1056, "top": 1033, "height": 48, "left": 331}, "words": "重症胜无力患:重定肌无力是种以接经肛肉接头处碱能活性减低为表现的痰"}, {"probability": {"variance": 0.004227, "average": 0.951815, "min": 0.808873}, "location": {"width": 411, "top": 1092, "height": 50, "left": 324}, "words": ":本品慎用于重症肌无力患省"}, {"probability": {"variance": 0.020007, "average": 0.917807, "min": 0.42781}, "location": {"width": 434, "top": 1179, "height": 34, "left": 326}, "words": "先天性成获得性QT期延长的患者"}, {"probability": {"variance": 0.017121, "average": 0.933264, "min": 0.555211}, "location": {"width": 980, "top": 1252, "height": 45, "left": 381}, "words": "有研究探了托特罗定速料片对QT间期的影参见【药理理】的“新床药理学"}, {"probability": {"variance": 0.017513, "average": 0.923883, "min": 0.48006}, "location": {"width": 1051, "top": 1316, "height": 38, "left": 336}, "words": "【药物相互作用】的“心脏的电生”),发现8ng/(治疗剂量2倍)时对QT间期的影响"}, {"probability": {"variance": 0.029272, "average": 0.881812, "min": 0.370134}, "location": {"width": 1060, "top": 1371, "height": 50, "left": 326}, "words": "大火于mg日对QT间期的影响,对YPZD6弱代谢者TM)QT间的影响大于对强代谢"}, {"probability": {"variance": 0.036303, "average": 0.868897, "min": 0.392568}, "location": {"width": 1063, "top": 1433, "height": 45, "left": 326}, "words": "者EM)QT间期的影响。托特罗定对QT的影响小丁莫西沙星服药4日后对QT"}, {"probability": {"variance": 0.032776, "average": 0.873169, "min": 0.458611}, "location": {"width": 1063, "top": 1490, "height": 48, "left": 326}, "words": "的影啊。但是可信区间有重叠对已知育QT间撕延长病史的惠求或正在服用IA类抗心"}, {"probability": {"variance": 0.041618, "average": 0.830152, "min": 0.429926}, "location": {"width": 1047, "top": 1552, "height": 45, "left": 331}, "words": "律央常(如:李丁、普鲁卡因胺)或I类抗心常药物(女,胺、索尔"}, {"probability": {"variance": 0.017583, "average": 0.927635, "min": 0.396541}, "location": {"width": 1060, "top": 1611, "height": 45, "left": 329}, "words": "的患者方本时,应考虑到这些情况参见【注意事项】的“药物相三作用”)。托特罗定"}, {"probability": {"variance": 0.025452, "average": 0.868878, "min": 0.46776}, "location": {"width": 1024, "top": 1673, "height": 43, "left": 331}, "words": "速释片及缓释别型全球上市后经验中未发现其与尖端转心律失常( Torsade ds Poilraa"}, {"probability": {"variance": 0.062281, "average": 0.753803, "min": 0.416845}, "location": {"width": 107, "top": 1739, "height": 32, "left": 329}, "words": "有相关"}, {"probability": {"variance": 0.021261, "average": 0.742782, "min": 0.512254}, "location": {"width": 114, "top": 1819, "height": 36, "left": 329}, "words": "患者指南"}, {"probability": {"variance": 0.016041, "average": 0.925792, "min": 0.361077}, "location": {"width": 1003, "top": 1890, "height": 43, "left": 384}, "words": "应告知总者抗毒残类药物:如托特罗定缓释胶囊,可能产生下列反应:、头"}, {"probability": {"variance": 0.033041, "average": 0.867581, "min": 0.377963}, "location": {"width": 1056, "top": 1950, "height": 48, "left": 331}, "words": "困倦:在确定药物对惠者是否会产生述影响前,应告知患者故重从事有潜危险性的"}, {"probability": {"variance": 0.010416, "average": 0.93498, "min": 0.675191}, "location": {"width": 178, "top": 2021, "height": 34, "left": 770}, "words": "第4贝,共14页"}, {"probability": {"variance": 0.023043, "average": 0.908151, "min": 0.477721}, "location": {"width": 137, "top": 2059, "height": 29, "left": 406}, "words": "Yo:20130502"}], "language": 3}